Thrombocytopenic patients requiring invasive surgery have few options to improve their platelet count preoperatively. This is a single-centre, retrospective review of thrombocytopenic patients receiving the thrombopoietin receptor agonist romiplostim perioperatively to allow for surgical interventions. Patient characteristics, romiplostim use, and surgical and safety outcomes (bleeding, thrombosis, transfusions) were collected and analysed. Forty-seven patients underwent 51 surgical procedures (ranging from total hip arthroplasty to open cardiac surgery) with romiplostim support. Thrombocytopenia aetiologies included immune thrombocytopenia, chronic liver disease, haematological malignancy, drug-related thrombocytopenia, and hereditary thrombocytopenia. Median (range) platelet counts improved, from 47
Thrombocytopenia in a patient requiring surgery frequently presents a barrier to surgical procedures. A positive correlation has been demonstrated between the degree of thrombocytopenia and risk of 30-day postoperative mortality (Glance et al, 2014) . Numerous negative perioperative outcomes have been shown to be more likely in thrombocytopenic patients, including increased risk of bleeding and sepsis as well as cardiac, pulmonary, and renal complications (Glance et al, 2014) . These concerns decrease the patient acceptance for procedures and may reduce the enthusiasm for procedures by the provider. Thrombocytopenia is typically managed in the perioperative period with platelet transfusion, a procedure that is costly and may be of limited or unpredictable benefit in certain patient groups, such as those with immune thrombocytopenia (ITP) or platelet alloimmunization (Carr et al, 1986; Schiffer et al, 2018) . Some patient groups, e.g.
Jehovah's Witnesses, may decline transfusion and therefore not be acceptable for some surgical procedures. More effective treatments are needed to manage perioperative thrombocytopenia.
The optimal platelet count for safe performance of any surgery is not known and probably varies according to the procedure and other patient variables. While guidelines from various professional societies recommend different thresholds based on the type of surgery being performed, data to support these recommendations is limited. Thresholds of 50, 80, and 100 9 10 9 /l have been proposed, depending on the type of surgery (British Committee for Standards in Haematology Blood Transfusion Task Force 2003; Kaufman et al, 2015) . Many additional individualized patient factors, such as platelet function, chronic liver or renal disease, known deficiency of clotting proteins or a history of perioperative bleeding, may further influence judgement of what is considered an "adequate" platelet count for surgery. Beyond the operative procedure itself, thrombocytopenia presents concern for risk of bleeding with airway manipulation, with cases reported of laryngeal bleeding complicating endotracheal intubation (Aiken & Collin, 1996) . Thrombopoietin receptor agonists are a new class of haematopoietic growth factors that have proven highly effective in the management of chronic immune thrombocytopenia, severe aplastic anaemia, and chronic hepatitis C-associated thrombocytopenia (Kuter et al, 2010; Afdhal et al, 2014; Desmond et al, 2014) . Romiplostim is a fusion protein comprised of four thrombopoietin receptor-activating 14-amino acid peptides conjugated to the Fc region of human IgG1 (to allow cellular recycling of the drug via the neonatal Fc receptor to increase its half-life) (Kuter, 2013) . Romiplostim currently has US Food and Drug Administration approval only for chronic ITP in adults, but studies demonstrating its efficacy in other settings, including chemotherapy-induced thrombocytopenia (Parameswaran et al, 2014; Soff et al, 2017; Al-Samkari et al, 2018) and myelodysplastic syndrome (Kantarjian et al, 2010; Sekeres et al, 2011; Giagounidis et al, 2014) , have been published. Romiplostim has been demonstrated to be safe and effective for over 5 years of continuous weekly treatment in patients with chronic ITP . A preliminary study of 18 patients receiving romiplostim for perioperative thrombocytopenia of numerous aetiologies was previously published by our group (Marshall et al, 2015) . The present study is the final analysis of the much larger cohort of perioperative thrombocytopenia patients treated with romiplostim at our institution from 2010 until 2017, including the 18 patients from the original study and 29 additional patients. In this analysis, we assessed the effect of romiplostim on the platelet count, time to platelet count ≥100 9 10 9 /l, and ability of patients to receive surgery without delay, bleeding, thrombosis and transfusion. Additionally, as compared with the preliminary study (Marshall et al, 2015) , more extensive evaluation, including subgroup analysis by aetiology of thrombocytopenia, was performed in this final analysis.
Methods
This study was approved by the Institutional Review Board (approval 2015P000152/PHS) of the Massachusetts General Hospital. Between 1 January 2010 and 1 April 2017, all patients aged ≥18 years who received romiplostim were identified via pharmacy records and the electronic medical record at Massachusetts General Hospital, and those receiving romiplostim specifically to increase platelet count in preparation for surgery were selected for further analysis. Patient data collected included: age, gender, cause(s) of thrombocytopenia, surgeries performed, delays or cancellations of surgery due to thrombocytopenia, platelet counts, dates and doses of romiplostim, red blood cell and platelet transfusions in the 14-day perioperative window (defined as 7 days preoperatively until 7 days postoperatively), bleeding and thrombotic events during romiplostim treatment and during the 14-day perioperative window, and date and cause of death or last known date alive. Statistical analysis was performed using Microsoft Excel 2016 (Microsoft Corp., Redmond, WA) and GraphPad Prism 7 (GraphPad, Inc., San Diego, CA).
Results

Baseline patient characteristics and procedures performed
Of 288 patients treated with romiplostim, 48 were treated to increase platelet counts to allow for surgical intervention. One patient was excluded from analysis due to incomplete data in the medical record. The 47 patients included for analysis underwent 51 discrete procedures for which romiplostim support was utilized. Procedures performed and patient demographics, including the aetiologies of thrombocytopenia (of which some patients had more than one) are shown in Table I . The median age was 61 (range, 24-94) years and 55% of patients were male. Causes of thrombocytopenia included ITP (25 patients), chronic liver disease (17 patients), haematological malignancy (5 patients), drugrelated aetiologies (5 patients) and hereditary thrombocytopenia (2 patients). All patients, including those with ITP, were initiated on romiplostim for the sole purpose of improving platelet count perioperatively to allow for surgery (i.e. no patients were being managed with romiplostim chronically prior to presentation). Most of the patients with ITP as a contributing aetiology of thrombocytopenia had mild disease, and none were on any chronic ITP treatment. The median duration of disease was 2Á5 years (range, 1 month to 30 years), 15 had no prior treatments for ITP, 5 had 1 prior treatment (prednisone), 3 had 2 prior treatments, and 2 had 3 prior treatments; only one patient had previously undergone splenectomy. Most procedures were major surgical operations: 13 cardiothoracic, 12 orthopaedic, 12 abdominopelvic and 4 neurosurgical. There were 10 other types of procedures performed (Table I) . The median (range) pre-procedure platelet count at initiation of romiplostim was 47 9 10 9 /l (9-120 9 10 9 /l). In all but 3 of the 51 procedures, the platelet count was <100 9 10 9 /l at the time of romiplostim initiation. The patients in the 3 procedures with platelet counts ≥100 9 10 9 /l at initiation identified as Jehovah's Witnesses (all had underlying mild ITP) and were supported with romiplostim prophylactically because of refusal to accept any blood products perioperatively; platelet count at initiation of romiplostim for these three cases ranged between 114 and 120 9 10 9 /l and their historic baseline was <100 9 10 9 /l. Of the remaining 48 procedures, platelet count at initiation was <75 9 10 9 /l in 83% and <50 9 10 9 /l in 60% of cases, and in all 48 cases the patient was not considered a suitable candidate for surgery solely due to thrombocytopenia.
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Romiplostim dosing. The median (and most common) starting dose of romiplostim was 3 lg/kg per week (range: 1-10 lg/kg per week). The mean romiplostim dose at the start of romiplostim was 3Á2 lg/kg per week [95% confidence interval (CI), 2Á7-3Á7 lg/kg per week] and the mean romiplostim dose at the time of the procedure was 3Á7 lg/kg per week (95% CI, 3Á2-4Á3 lg/kg per week) ( Fig 1A) . Each week, platelet counts were measured before romiplostim administration. One or more romiplostim dose changes were made in 24 cases (47%) and romiplostim was weaned off (dose was halved weekly for 2-3 weeks prior to discontinuation) at the end of treatment in 12 cases (24%). A measured platelet count >400 9 10 9 /l triggered a dose reduction of 25-50%. Dose escalation of 25-50% was typically implemented for measured platelet count <50 9 10 9 /l but was also occasionally undertaken to a greater degree or at higher platelet counts at the discretion of the treating haematologist.
Platelet response. Of the 48 cases with baseline platelet counts <100 9 10 9 /l, a median duration of 13 (range, 6-35) days of romiplostim therapy was required to achieve a platelet count ≥100 9 10 9 /l, a threshold considered as "therapeutic" in most cases. In these cases, a platelet count of ≥100 9 10 9 /l was achieved in 94% of cases overall (it was never achieved in 3 cases), with this target achieved in 92% of cases after 3 doses of romiplostim, 79% of cases after 2 doses and 38% of cases after a single dose. The median time to peak preoperative platelet count (median 177 9 10 9 /l) was 19 (range, 4-47) days. Median platelet count at the time of surgery was 164 9 10 9 /l, a statistically significant increase compared with the median platelet count at romiplostim initiation (P < 0Á0001 by Wilcoxon signed-rank test) (Fig 1B) . Median platelet counts for the entire cohort over the perioperative window are shown in Fig 2 and complete treatment courses for two illustrative patients are illustrated in Fig 3. During romiplostim treatment, 80% and 71% of all recorded weekly platelet counts were ≥75 and ≥100 9 10 9 /l, respectively. Except possibly for patients with haematological malignancy, there was little difference in the platelet response to romiplostim dose when subgroup analyses were performed based on the underlying aetiology of thrombocytopenia (Table II) . Procedure, transfusion and safety outcomes
Operations were performed on the pre-planned operative date without delay in 96% of cases. During the 14-day perioperative window, red blood cell transfusion was given in 6 cases and platelet transfusion was given in 3 cases, with no platelet transfusion given due to bleeding (a patient received 2 units of platelets immediately prior to a spinal fusion procedure at a platelet count of 99 9 10 9 /l; a patient received 1 unit of platelets on postoperative day 1 following right upper lobectomy and pleurectomy for resection of lung cancer at a platelet count of 184 9 10 9 /l; and a patient received 2 units of platelets preoperatively prior to a 3-vessel coronary artery bypass graft operation at a platelet count of 95 9 10 9 /l).
While receiving romiplostim, 1 patient had bilateral peroneal deep venous thromboses on postoperative day 8 after undergoing pneumonectomy with a platelet count of 197 9 10 9 /l and 1 patient had a Foley catheter-associated urethral clot 1 day after undergoing holmium laser enucleation of the prostate with a platelet count of 48 9 10 9 /l. Four patients had bleeding events: 3 within 2 days of surgery (following total hip arthroplasty, transarterial chemoembolization and dental extraction) and 1 (following open cardiac surgery) on postoperative day 19; all were World Health Organization grade 3, and occurred at platelet counts ranging from 82 to 185 9 10 9 /l. Types of bleeding included thigh haematoma in 1 patient, gastrointestinal bleeding in 2 patients, and oozing after dental extraction in one patient.
Discussion
Thrombocytopenia is a common haematological problem that is frequently chronic. While many patients with ITP, chronic liver disease or primary bone marrow disorders may live day-to-day without excessive bleeding or bruising at platelet counts far below the normal range, bleeding risk increases greatly if challenged by surgical procedures. Surgeons are therefore often hesitant to operate on these patients out of concern for bleeding complications. Patients may also refuse needed procedures out of similar concerns. While platelet transfusions may be effective in raising the platelet count in the perioperative setting in many patients, it may not be effective in some (due to ITP or alloimmunization) and may refused by others (e.g. Jehovah's Witnesses). There is clearly a need for alternatives to platelet transfusion.
Before the present study, four studies explored the efficacy of romiplostim for the management of perioperative thrombocytopenia:
• The first was a randomized pilot study examining use of romiplostim, eltrombopag or platelet transfusion preoperatively in thrombocytopenic patients (platelet count <60 9 10 9 /l) with chronic liver disease requiring outpatient percutaneous liver biopsy (Basu et al, 2012) . Sixtyfive patients were randomized 1:1:1 to receive a single 500 lg dose of romiplostim 2 weeks prior to the planned procedure, eltrombopag 75 mg daily for 2 weeks prior to the planned procedure, or 7 units of platelet transfusion the night prior to the procedure. All three groups had a mean platelet count of >180 9 10 9 /l at the time of the procedure, but the wholesale acquisition cost was noted to be lowest with romiplostim (US$2284) as compared with eltrombopag (US$2991) or platelet transfusion (US$7500).
• The second study prospectively examined the efficacy of fixed-dose romiplostim (2 lg/kg weekly) in 35 male patients with thrombocytopenia due to hepatitis C-associated liver cirrhosis undergoing elective surgical procedures, mostly minor in nature [e.g. cataract surgery (31%), hernia repair (31%)] (Moussa & Mowafy, 2013) . Prior to entering the study, patients had failed treatment with standard therapy, including platelet transfusion; a platelet threshold of at least 70 9 10 9 /l was required to proceed to surgery. Thirty-three patients (94%) achieved this threshold after 18-39 days of romiplostim treatment and could undergo surgery. No serious adverse events attributable to romiplostim were noted, and there were no postoperative bleeding or thrombotic events.
• The third published study, performed by our group, was an 18-patient, 22 procedure cohort, including patients with numerous aetiologies of thrombocytopenia undergoing a wide range of procedures (Marshall et al, 2015) . In this study, all patients could receive surgery without delay or cancellation; there were no venous thromboembolic events and four bleeding events. The present study is the predecessor to this study, increasing the number of patients nearly three-fold.
• The fourth published study was a retrospective cohort of 22 chronic ITP patients refractory to intravenous immunoglobulin and glucocorticoids who required a wide range of elective surgical procedures (approximately half were major operations). With romiplostim support, all patients could undergo surgery; no major bleeding or thromboembolic events were reported (Ramakrishna et al, 2015) .
While there is limited data available examining perioperative use of romiplostim, a peptide thrombopoietin receptor agonist, there has been extensive investigation of the nonpeptide thrombopoietin receptor agonists for the management of perioperative thrombocytopenia in patients with chronic liver disease:
• A large, randomized, controlled trial of 292 adults with thrombocytopenia secondary to chronic liver disease was performed, in which eltrombopag or placebo was administered for 14 days prior to an elective procedure performed within 5 days of the final eltrombopag dose (Afdhal et al, 2012) . Eltrombopag was highly effective in obviating the need for platelet transfusion, with 72% of patients that received eltrombopag avoiding platelet transfusion perioperatively as compared with 19% of those receiving placebo; unfortunately, this study was halted early due to an increased rate of portal vein thrombosis in the eltrombopag arm (6 events) versus the placebo arm (1 event). An increase in the rate of venous thromboembolism (VTE) with use of eltrombopag in patients with chronic liver disease was also seen in a randomized, controlled trial of eltrombopag versus placebo as support during antiviral therapy for hepatitis C (Afdhal et al, 2014 ).
• Lusutrombopag is a novel non-peptide thrombopoietin receptor agonist that has also been studied for this indication. In a phase 3, randomized controlled trial, adults with thrombocytopenia secondary to underlying chronic liver disease were randomized to lusutrombopag versus placebo for up to 7 days prior to a planned minor surgical procedure (such as endoscopic variceal ligation, endoscopy or dental extraction) to be performed several days later (Afdhal et al, 2017) . Lusutrombopag was effective in raising the platelet count, which was ≥50 9 10 9 /l in 64Á8% of lusutrombopagtreated patients compared with 29Á0% of placebo-treated patients (P < 0Á0001). There was no increased incidence of portal vein thrombosis in patients receiving lusutrombopag.
• Avatrombopag is another novel oral non-peptide thrombopoietin receptor agonist showing comparable benefit in the management of perioperative thrombocytopenia in chronic liver disease patients undergoing procedures. Two randomized, controlled trials enrolling a total of 435 patients demonstrated a 40-50% reduction in need for platelet transfusion or rescue for bleeding with avatrombopag (Terrault et al, 2017) . There was no increased rate of portal vein thrombosis.
Our current study assesses the outcomes of the largest cohort of patients receiving romiplostim to enable surgery. It is unique in several ways. It demonstrates the efficacy of romiplostim in raising the platelet count perioperatively in patients with a wide variety of underlying aetiologies of thrombocytopenia, not just chronic liver disease-associated thrombocytopenia or chronic ITP, as did the other published studies. Most patients underwent major surgical procedures, such as open cardiac surgery (18% of all cases) and total hip arthroplasty (12% of all cases), whereas in other studies all or most procedures were more minor in nature, such as endoscopies or dental extractions. As in the other studies, romiplostim was highly effective in raising the platelet count and allowed procedures to be performed that might not otherwise have been done, probably obviating the need for platelet transfusion. All patients demonstrated increased platelet counts at the time of surgery compared with the time of romiplostim initiation. In all but 2 operative cases, surgery could proceed on schedule without delay or cancellation. The median platelet count at the time of surgery was 164 9 10 9 /l, a 3Á5-fold, statistically significant increase from the median platelet count of 47 9 10 9 /l at the time of romiplostim initiation. When considering subgroup analyses, examining romiplostim dosing and platelet count response by specific underlying aetiologies of thrombocytopenia, only patients with haematological malignancy had a median platelet count <100 9 10 9 /l at the time of surgery. Despite this poorer response to romiplostim support, all five patients with haematological malignancies underwent surgery on schedule and without bleeding complications. There were no apparent adverse effects of romiplostim administration in our study. This is consistent with other studies of romiplostim, which suggest it is generally well-tolerated (Bussel et al, 2006 (Bussel et al, , 2009 . Ten patients developed platelet counts ≥400 9 10 9 /l on at least one measurement, prompting dose reduction. One patient developed postoperative VTE (bilateral distal deep venous thrombosis on postoperative day 9); this patient was septic and critically ill in the surgical intensive care unit at the time of this thrombotic event, with a platelet count of 197 9 10 9 /l. Bleeding occurred in 4 cases at platelet counts between 82 9 10 9 /l and 185 9 10 9 /l, so the contribution of thrombocytopenia to this bleeding is uncertain, but unlikely. During a pre-specified 14-day perioperative window, red blood cell transfusion was given in 6 cases and platelet transfusion in only 3 cases; 94% of patients avoided platelet transfusion entirely. Therefore, rates of transfusion and postoperative VTE and bleeding were not atypical for a non-thrombocytopenic population undergoing mostly major surgery. Our study did not involve bone marrow evaluation of patients before initiation and following discontinuation of romiplostim treatment to monitor for possible increased reticulin fibrosis of the marrow, but the total duration of exposure to this drug was under 3 months in 90% of cases; even with much longer courses of romiplostim over 3 years, the incidence of fibrosis is very low (2-3%) and typically reverses following discontinuation of drug Janssens et al, 2016) . Romiplostim was tapered off in some ITP patients due to the concern that Romiplostim for Perioperative Thrombocytopenia ª 2018 John Wiley & Sons Ltd abrupt discontinuation is associated with a 13% rate of rebound worsening of thrombocytopenia when treating ITP patients (Bussel et al, 2006) ; there is no such concern for patients without ITP. There are several notable limitations of this study: (i) It was a retrospective study with no randomization or blinding and hence the magnitude of the treatment effect, if any, of romiplostim on the procedure itself, its bleeding risk or use of transfusion cannot be measured. However, such a study could probably not be performed in patients undergoing major surgical procedures, even compared with platelet transfusion, (ii) Patients underwent a wide variety of surgical procedures, each with a differing risk of bleeding and postoperative VTE. There was no specific, uniform platelet count threshold for proceeding to surgery; the threshold was roughly set by most surgeons to be ≥100 9 10 9 /l but this was not universal, and several patients were taken to surgery with platelet counts lower than this, (iii) Romiplostim dosing was imprecise. Although a majority of patients increased their platelet count to >100 9 10 9 /l after 2 weekly doses of approximately 3 lg/kg, there was a wide range of starting doses and no standard for dose modification. However, despite the lack of a delineated protocol for romiplostim dosing, a platelet count of ≥100 9 10 9 /l was achieved in 94% of cases.
In patients with chronic thrombocytopenia who require elective surgical procedures, this study provides evidence that romiplostim is safe and rapidly increases the platelet count in most patients to allow procedures, including major cardiac, orthopaedic and neurological surgery, to proceed safely and on schedule. Although romiplostim is a widely-used supportive care modality at our institution, the magnitude of its benefit and ultimate impact on surgical outcomes requires additional rigorous study. The management of perioperative thrombocytopenia remains an off-label use of romiplostim.
